| Literature DB >> 33299484 |
Giovanna Bosica1, Kaylie Demanuele1, José M Padrón2, Adrián Puerta2.
Abstract
A rapid route for obtaining unsymmetrical 1,2-dihydropyridines (1,2-DHPs) as opposed to 1,4-dihydropyridines (1,4-DHPs) has been achieved via a one-pot multicomponent Hantzsch reaction. A benign protocol has been developed for the preparation of various 1,2-dihydropyridine derivatives using heterogenized phosphotungstic acid on alumina support (40 wt %). High yields of over 75% have been accomplished in just 2-3.5 h after screening several heterogeneous catalysts and investigating the optimal reaction conditions. The catalyst chosen has passed the heterogeneity test and was shown to have the potential of being reused for up to 8 consecutive cycles before having a significant loss in activity. In addition, aromatic aldehydes gave the aforementioned regioisomer while the classical 1,4-DHPs were obtained when carrying out the reaction using aliphatic aldehydes. The preliminary study of the antiproliferative activity against human solid tumor cells demonstrated that 1,2-DHPs could inhibit cancer cell growth in the low micromolar range.Entities:
Keywords: 1,2-dihydropyridines; antiproliferative activity; green Hantzsch synthesis; heterogeneous catalysis; one-pot multicomponent reaction
Year: 2020 PMID: 33299484 PMCID: PMC7705860 DOI: 10.3762/bjoc.16.235
Source DB: PubMed Journal: Beilstein J Org Chem ISSN: 1860-5397 Impact factor: 2.883
Scheme 1The classical Hantzsch synthesis between benzaldehyde (1a), ethyl acetoacetate (2), and ammonium acetate (3) as well as the synthesis highlighted in this work.
Screening of acidic heterogeneous catalysts.
| entrya | catalyst | yield (%)b | reaction time (h) |
| 1 | Nafion® NR-50 | 88 | 5 |
| 2 | Nafion® SAC-13 | 96 | 5 |
| 3 | montmorillonite K30 | 72 | 4.5 |
| 4 | Dowex® 50W | 48 | 5.5 |
| 5 | Amberlyst® 15 | 68 | 5.5 |
| 6c | activated Amberlyst® 15 | 82 | 5 |
| 7 | 40 wt % silicotungtstic acid on cellulose | 49 | 6 |
| 8 | 40 wt % silicotungstic acid/Al2O3 | 37 | 6 |
| 9 | 40 wt % phosphotungstic acid (PW)/SiO2 | 61 | 6 |
| 10 | 20 wt % silicotungstic acid/montmorillonite K10 | 40 | 6 |
| 11d | 30 wt % PW/montmorillonite K30 | 83 | 2.5 |
| 12 | 40 wt % PW/Al2O3 | 94 | 3.5 |
| 13 | 40 wt % PW/acidic Al2O3 | 85 | 4 |
| 14 | 30 wt % PW/Amberlyst® 15 | 80 | 4.5 |
| 15 | 50 wt % H3PO4/Al2O3 | 74 | 5 |
| 16 | 30 wt % phosphomolybdic acid/Amberlyst® 15 | 43 | 6 |
aReaction carried out under neat conditions using 0.04 g/mmol of the catalyst and a 1a/2/3 1:2:1 ratio. bYield of the pure isolated product. cActivation by heating overnight at 100 °C. d1a/2/3 1:2:2 ratio.
Figure 1Optimization trials with the selected solid catalysts.
Screening of different substrates.
| producta | R | yield of | time (h) |
| C6H5 ( | 94 | 4.5 | |
| 2-OH-C6H4 ( | 73 | 3.5 | |
| 2,4-(OH)2-C6H3 ( | 96 | 4 | |
| 2,4-Cl2-C6H3 ( | 65 | 6 | |
| 3-CH3O-C6H4 ( | 62 | 5 | |
| 2-CH3O-C6H4 ( | 62 | 5.5 | |
| 4-CH3-C6H4 ( | 64 | 4.5 | |
| 4-N(CH3)2-C6H4 ( | 92 | 4 | |
| naphthyl ( | 90 | 4 | |
| 2,3-(methylenedioxy)-C6H3 ( | 81 | 4.5 | |
aThe reactions were performed on a 5 mmol scale under neat conditions at room temperature and in the presence of 0.04 g/mmol 40 wt % PW on alumina at a molar ratio of 1:2:1. bPure isolated product.
Results obtained when using the aliphatic aldehydes 1 in the Hantzsch synthesis.
| producta | aldehyde | yield of | time (h) |
| cyclohexanal ( | 82 | 4 | |
| penten-2-al ( | 79 | 4 | |
aThe reactions were performed on a 5 mmol scale under neat conditions at room temperature and in the presence of 0.04 g/mmol 40 wt % PW on alumina at a molar ratio of 1:2:1. bPure isolated product.
Figure 2Graphical representation of the results obtained in the reusability test.
Antiproliferative activity (GI50 values) of selected 1,2-DHPs against human solid tumor cells.a
| compound | cell line | |||||
| A549 | HBL-100 | HeLa | SW1573 | T-47D | WiDr | |
| 29 ± 4.6 | 23 ± 1.8 | 21 ± 2.0 | 31 ± 0.7 | 21 ± 2.5 | 22 ± 2.4 | |
| >100 | >100 | 28 ± 7.5 | >100 | >100 | >100 | |
| 14 ± 3.1 | 19 ± 3.0 | 12 ± 4.5 | 22 ± 1.2 | 17 ± 3.6 | 17 ± 1.2 | |
| 43 ± 14 | 42 ± 6.2 | 26 ± 4.0 | 49 ± 12 | 33 ± 5.1 | 41 ± 9.6 | |
| 18 ± 4.9 | 20 ± 0.9 | 22 ± 6.6 | 18 ± 6.8 | 22 ± 2.1 | 18 ± 1.6 | |
| 34 ± 4.7 | 38 ± 4.0 | 28 ± 4.6 | 33 ± 6.1 | 31 ± 0.9 | 39 ± 8.9 | |
| 23 ± 6.8 | 26 ± 2.0 | 18 ± 5.0 | 30 ± 0.3 | 20 ± 2.0 | 33 ± 4.8 | |
| 16 ± 6.7 | 16 ± 3.5 | 11 ± 1.7 | 15 ± 1.9 | 19 ± 3.3 | ||
| CDDP | 17 ± 3.3 | 23 ± 4.3 | ||||
aGI50 values are given in µM. The standard deviation was calculated from at least two independent experiments. CDDP (cisplatin) was used as a reference compound. Values in bold face represent the best antiproliferative data against tumor cell lines (GI50 < 10 µM).